Litcius/Paper detail

Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint

Kuan Hu, Lin Xie, Masayuki Hanyu, Yiding Zhang, Lingyun Li, Xiaohui Ma, Kotaro Nagatsu, Hisashi Suzuki, Weizhi Wang, Ming‐Rong Zhang

2020RSC Chemical Biology22 citationsDOIOpen Access PDF

Abstract

Interface peptides that mediate protein-protein interactions (PPI) are a class of important lead compounds for designing PPI inhibitors. However, their potential as precursors for radiotracers has never been exploited. Here we report that the interface peptides from programmed death-ligand 1 (PD-L1) can be used in positron emission tomography (PET) imaging of programmed cell death 1 (PD-1) with high accuracy and sensitivity. Moreover, the performance differentiation between murine PD-L1 derived interface peptide (mPep-1) and human PD-L1 derived interface peptide (hPep-1) as PET tracers for PD-1 unveiled an unprecedented role of a non-critical residue in target binding, highlighting the significance of PET imaging as a companion diagnostic in drug development. Collectively, this study not only provided a first-of-its-kind peptide-based PET tracer for PD-1 but also conveyed a unique paradigm for developing imaging agents for highly challenging protein targets, which could be used to identify other protein biomarkers involved in the PPI networks.

Topics & Concepts

Positron emission tomographyPD-L1Immune checkpointInterface (matter)Immune systemCancer researchMaterials scienceMedicineNuclear medicineImmunotherapyImmunologyCapillary actionComposite materialCapillary numberCancer Immunotherapy and BiomarkersNanoplatforms for cancer theranosticsPeptidase Inhibition and Analysis
Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint | Litcius